Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 57Carcinoma, Non-Small-Cell Lung 46Ovarian Neoplasms 31Stomach Neoplasms 22Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Lung Neoplasms 18Neoplasm Metastasis 17Fallopian Tube Neoplasms 14Triple Negative Breast Neoplasms 13Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 10Colorectal Neoplasms 9Carcinoma, Ovarian Epithelial 9Melanoma 8Head and Neck Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Carcinoma, Renal Cell 6Adenocarcinoma of Lung 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Solid Tumors 5Testicular Neoplasms 4Testicular Germ Cell Tumor 4Recurrence 4Carcinoma, Transitional Cell 4

Interventions

regorafenib 1Paclitaxel 1Everolimus 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unresectable Locally Advanced or Metastatic Solid Tumors × Paclitaxel × Clear all
NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡